澳优(01717.HK)一季度经调整净利润增长11%至3.31亿元 自家品牌配方牛奶粉业务收入升36.5%
格隆汇5月11日丨澳优(01717.HK)发布公告，截至2021年3月31日止3个月，公司收入21.83亿元人民币，同比增长12.9%；毛利11.16亿元，同比增长7.2%；公司拥有人应占净利润3.31亿元，同比增长22.9%；经调整公司拥有人应占净利润3.31亿元，同比增长11%。
自家品牌配方牛奶粉业务表现依然理想，录得收入人民币10.53亿元，同比增长36.5%。尤其是海普诺凯1897业务单元于2021年第一季录得收入人民币7.18亿元，同比增长58.7%，继续为集团增长最快的业务单元。
集团在中国的自家品牌配方羊奶粉业务亦于2021年第一季复苏，录得收入人民币8.35亿元，与上一个回顾季度环比增长29.7%。公司认为，自家品牌配方奶粉业务复苏且持续增长归功于集团迅速调整策略以应对市场转变，加上坚持拥抱母婴店渠道，以高频次高质量消费者活动赋能渠道。
集团积极响应市场发展，继续于此一范畴大力推动研发投资。集团的努力得到理想结果。中国国家市场监督管理总局于2021年4月25日批准集团注册为乳糖不耐症婴儿而设的特殊医学用途婴儿无乳糖配方食品。同日，中国国家卫生健康委员会批准集团联营公司锦旗生物集团(Bioflag International Corporation)就MP108鼠李糖乳杆菌(lactobacillus rhamnosusMP108)（一种新食材菌株，有助预防多种小儿炎症）在中国使用提交的申请。鼠李糖乳杆菌乃首支由中国公司开发并获准在中国用于婴幼儿食品的菌株，标志着中国市场在此方面的一大突破。集团营养品业务方面，过去大部分Nutrition Care的营养品均于澳洲生产，但受到供应能力的限制。
为解决供应能力的限制及更有效地支持集团在中国市场的发展，集团决定将Nutrition Care部份产品转由中国进行生产。相应技术检核已在进行，公司将于本年第二季开始在中国生产部分营养品。集团未来将继续以科学化的方式审慎推动业务发展和增长，紧贴最新趋势，将产品组合从婴儿拓展至儿童及成人营养品，进一步促进消费者健康成长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
